Development of Anti-VEGF Receptor/Flk-1 Immunoliposomes for Cytotoxic Anti-Angiogenesis Therapy
Abstract
We hypothesized that tumor-associated endothelium can be targeted with chemotherapy-loaded immunoliposomes (ILs) directed against VEGF Receptor 2 (VEGFR2, F1K- 1, KDR). VEGFR2 is the primary receptor for VEGF-mediated tumor angiogenesis, and as a cell surface receptor on endothelial cells provides a highly accessible target for immunoliposome therapy. Accordingly, we have developed anti-VEGFR2 ILs to deliver highly potent chemotherapeutics to VEGFR2- expressing endothelial cells for cytotoxic antiangiogenic treatment. Cloned anti-VEGFR2 scFv 4G7 sequences were expressed in E. coli, and purified scFv containing a C-terminal cysteine residue were conjugated to liposomes using three different strategies.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2000
- Accession Number
- ADA390405
Entities
People
- John W. Park
Organizations
- University of California, San Francisco